NEW YORK, April 12, 2011 (GLOBE NEWSWIRE) -- Alliqua, Inc. (OTCBB:ALQA) (Frankfurt:HL1) ("Alliqua"), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced the filing of a provisional patent application for its transdermal delivery technology with the U.S. Patent and Trademark Office. The filing was based on positive results from recent studies that showed Alliqua's hydrogel based patch technology successfully delivering an active pharmaceutical ingredient ("API") with greater potential efficacy from both a time of onset and duration perspective. The patent application covers several specific characteristics of the technology and formulations which management believes are unique to its platform.
"Filing the patent on these important innovations is a significant step towards securing our intellectual property position and moving forward with potential strategic relationships and commercialization," said Matthew Harriton, CEO of Alliqua Biomedical, "We anticipate adding to the breadth of these filings as we further study the technology and its applications."
David Stefansky, Chairman of Alliqua, stated, "These filings demonstrate our continued efforts to develop intellectual property, which is protected and defensible and to insure the long-term commercial position of our products."
About Alliqua Inc.
Alliqua, Inc. (OTCBB:ALQA) ("Alliqua"), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.
AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate™.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
For additional information, please visit
To receive future press releases via email, please visit:
The Alliqua, Inc. logo is available at
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our most recent Form 10-Q and Form 10-K filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at . We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Alliqua, Inc. Steven Berger 646-218-1450
